UCB S.A. operates as a biopharmaceutical company that focuses on three therapeutic areas – the central nervous system (CNS), inflammation and immunology (including allergy), and oncology in Belgium. The company operates in approximately 40 countries worldwide. Its major global markets include the U.S., Europe and Japan. UCB’s major pharmaceutical products include: Keppra (levetiracetam) Keppra is an antiepileptic, which significantly reduces the frequency of epileptic attacks. Keppra is indicated as an add-on therapy for partial onset seizures with or without secondary generalized seizures for epilepsy patients aged approximately 16 years. Keppra was filed in the U.S. in December 2004 and in Europe in March 2005, as an application for a new intravenous formulation. In the fourth quarter of 2004, the company also filed a paediatric indication of Keppra (for patients aged 4-16) in the U.S. and Europe. Xyzal (levocetirizine) and Zyrtec (cetirizine) Xyzal (levocetirizine) and Zyrtec (cetirizine) are antiallergics prescribed for seasonal rhinitis, perennial rhinitis and chronic idiopathic urticaria. A Phase III EPAAC study (Early Prevention of Asthma in Atopic Children) is underway to test the hypothesis that Xyzal can delay the onset of asthma in atopic children. Xyrem Xyrem is the FDA-approved medication for the treatment of cataplexy (sudden loss of control over voluntary muscle movement) associated with narcolepsy. Nootropil (piracetam) Nootropil is a cerebral function regulator and first in the class of ‘nootropic’ agents. Atarax Atarax (hydroxyzine) is a non-benzodiazepinic tranquilliser. Lortab Lortab (hydrocodone-paracetamol), an analgesic, which reduces sensitivity to most types of pain. Tussionex Tussionex is the 12-hour hydrocodone-based prescription syrup for coughs and colds, enabling UCB to offer a range of respiratory therapies. Metadate CD / Equasym XL Unique extended-release formulation of the most commonly used treatment of Attention Deficit and Hyper activity Disorder (ADHD). Marketed in the U.S. as Metadate CD, this once-daily methylphenidate has an extended release formulation, enabling children to maintain their attention throughout the school day more effectively, without affecting their appetite or sleep patterns in the evening. The company intends to launch it in Europe in 2005 under the brand name Equasym XL. In February 2005, Equasym XL was approved for marketing and launched in the UK. Dipentum Dipentum is a treatment for ulcerative colitis. Somatostatin-UCB Somatostatin-UCB is for the treatment of patients suffering from haemorrhaging of the oesophagus and post-operative gastro-intestinal fistulas. Brivaracetam (UCB34714) Brivaracetam is a broad-spectrum product in development. Phase II clinical trials including patients with photosensitive epilepsy produced preliminary results suggesting the compound is more potent than Keppra and provides suppression of light-induced electro encephalogram (EEG) abnormalities. Brivaracetam has also demonstrated some preclinical activity in the treatment of neuropathic pain and essential tremor. Seletracetam (UCB4412) Seletracetam is a SV2A ligand in development. Seletracetam reduces high-voltage-activated calcium currents, providing UCB with another avenue for tackling the heterogeneous nature of epilepsy. A Phase I clinical trial has indicated that this compound is well tolerated and preclinically even more potent than Keppra. Attention deficit/hyperactivity disorder (ADHD) CDP323 CDP323 has potential in tackling the inflammation associated with several major diseases. Preclinical data demonstrates activity in multiple sclerosis, rheumatoid arthritis and asthma. There is additional potential for this product in psoriasis. CDP323 is a smallmolecule inhibitor of alpha-4 integrins. Its mechanism of action is to stop white blood cells migrating to and exacerbating areas of inflammation. As a small molecule, it can be taken orally. CDP323 completed a Phase I multipledose study. Efletirizine Efletirizine is a novel antihistamine with a promising onset of action and safety profile.
ucb sa (UCB:EN Brussels)
Allée de la Recherche, 60
Phone: 32 2 559 99 99
Fax: 32 2 559 99 00www.ucb.com
|Grifols SA||€33.00 EUR||+0.20|
|Hospira Inc||$53.64 USD||+0.20|
|K+S AG||€24.16 EUR||+0.03|
|Mylan Inc/PA||$48.38 USD||+0.379|
|Valspar Corp/The||$80.47 USD||+0.46|
|View Industry Companies|
Sponsored Financial Commentaries
To contact UCB SA, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.